Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 10
Submit an article Journal homepage
771
Views
19
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor

Kazuo OdaAnalysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc., Osaka, Japan, Correspondence[email protected]
,
Ying J. CaoDrug Discovery Science & Management-US, Astellas Research Institute of America LLC, Northbrook, IL, USA,
,
Taiji SawamotoClinical Pharmacology, Astellas Pharma Inc., Tokyo, Japan, and
,
Naoyuki NakadaAnalysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc., Osaka, Japan,
,
Ogert FisnikuBioanalysis-US, Astellas Research Institute of America LLC, Skokie, IL, USA
,
Yasuhisa NagasakaAnalysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc., Osaka, Japan,
&
Kin-ya SohdaAnalysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc., Osaka, Japan,
show all
Pages 887-902 | Received 20 Jan 2015, Accepted 04 Mar 2015, Published online: 19 May 2015

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yoshiya Tanaka & Hiroyuki Izutsu. (2020) Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opinion on Pharmacotherapy 21:9, pages 1015-1025.
Read now

Articles from other publishers (18)

E.J. Corey & Yong‐Jin Wu. 2023. Molecules Engineered Against Oncogenic Proteins and Cancer. Molecules Engineered Against Oncogenic Proteins and Cancer 144 186 .
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development 137 174 .
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem & Ahmed M. Gouda. (2022) A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics 14:5, pages 1001.
Crossref
Akito Nishimura, Masayuki Tateiwa, Shuuitirou Tajima & Takuya Tada. (2022) Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis. Journal of Rural Medicine 17:3, pages 193-195.
Crossref
Donald J. AbrahamRobert M. Borzilleri, Amy C. Hart, Ryan Moslin, John S. Tokarski & Stephen T. Wrobleski. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 1 86 .
Junko Toyoshima, Mai Shibata, Atsunori Kaibara, Yuichiro Kaneko, Hiroyuki Izutsu & Tetsuya Nishimura. (2020) Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology 87:4, pages 2014-2022.
Crossref
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tsuyoshi Kiyota, Atsushi Kambayashi & Tetsuya Nishimura. (2020) The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers. Clinical Pharmacology in Drug Development 10:3, pages 283-290.
Crossref
Tong Zhu, Selina Moy, Udaya Valluri, Ying Cao, Wenhui Zhang, Taiji Sawamoto, Vishala Chindalore & Bola Akinlade. (2020) Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis. Clinical Drug Investigation 40:9, pages 827-838.
Crossref
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda & Tetsuya Nishimura. (2020) A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. European Journal of Clinical Pharmacology 76:8, pages 1135-1141.
Crossref
Daisuke Miyatake, Tomohisa Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tetsuya Nishimura, Masataka Katashima, Masashi Sakaki, Kazuaki Inoue, Takayoshi Ito, Naoki Uchida, Kenichi Furihata & Akinori Urae. (2019) Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function. Clinical Pharmacology in Drug Development 9:6, pages 699-708.
Crossref
Mai Shibata, Toshifumi Hatta, Masako Saito, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda & Tetsuya Nishimura. (2020) Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects. Clinical Drug Investigation 40:5, pages 469-484.
Crossref
Daisuke Miyatake, Tomohisa Shibata, Mai Shibata, Yuichiro Kaneko, Kazuo Oda, Tetsuya Nishimura, Masataka Katashima, Hisakuni Sekino, Kenichi Furihata & Akinori Urae. (2019) Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function. Clinical Drug Investigation 40:2, pages 149-159.
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2019) Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina Clínica 152:9, pages 353-360.
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2019) JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina Clínica (English Edition) 152:9, pages 353-360.
Crossref
Daisuke Miyatake, Naoyuki Nakada, Akitsugu Takada, Kota Kato, Yuta Taniuchi, Masataka Katashima & Taiji Sawamoto. (2018) A phase I, open-label, single-dose micro tracer mass balance study of 14 C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry. Drug Metabolism and Pharmacokinetics 33:2, pages 118-124.
Crossref
Tong Zhu, Corrie Howieson, Tomasz Wojtkowski, Jay P. Garg, David Han, Ogert Fisniku & James Keirns. (2017) The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor. Clinical Pharmacology in Drug Development 6:6, pages 548-555.
Crossref
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni & Daniella M. Schwartz. (2017) JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:5, pages 521-546.
Crossref
Ying Jun Cao, Taiji Sawamoto, Udaya Valluri, Kathy Cho, Michaelene Lewand, Suzanne Swan, Kenneth Lasseter, Mark Matson, John HolmanJrJr, James Keirns & Tong Zhu. (2016) Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects. Clinical Pharmacology in Drug Development 5:6, pages 435-449.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.